Identification of a new Type II Heat-labile Enterotoxin

One of the factors limiting the commercial development of mucosal vaccines is the availability of appropriate, safe and effective adjuvants and antigen delivery systems that promote the desired kinds of immune responses. In addition, many of the new subunit vaccine candidates lack sufficient immunogenicity to be clinically effective. Microbiologists at the University at Buffalo have designed a variety of novel vaccine adjuvants that demonstrate an ability to stimulate mucosal and systemic immune responses against either co-administered or coupled vaccine antigens. Further, their design should avoid problems of toxicity, which have precluded the use of other enterotoxin-based adjuvants in human vaccines. These adjuvants offer the potential f or inclusion in both mucosal and systemic vaccines, regardless of whether the vaccines are intended for prophylactic or therapeutic use.

Categories: Other, Therapeutic and Vaccines

Type of Offer: Licensing



Next Patent »
« More Pharmaceutical Patents
« More Medical Patents

Share on      


CrowdSell Your Patent